Clinical influencing factors of in-stent restenosis in acute coronary syndrome patients with CYP2C19 intermediate metabolize

吴天源,李韶南,罗义,吕磊,孙少喜

DOI: https://doi.org/10.3969/j.issn.1672-5301.2017.12.012

2017-01-01

Abstract:Objective To explore the clinical influencing factors of in-stent in acute coronary syndrome patients with CYP2C19 Intermediate Metabolize.Methods The CYP2C19 gene polymorphism was detected in 308 patients with ACS who were admitted to Department of cardiology from January 2014 to April 2016,among them,120 patients with CYP2C19 Intermediate metabolize were enrolled.The PCI patients were followed up for 12 months and the coronary angiography was performed at our hospital.ISR standard was more than 50％ of coronary artery lesion compared with the original diameter.The patients were divided into ISR group(n=38) and no restenosis group (n=82) according to absence or presence of in-stent restenosis.Multivariate Logistic regression was used to identify independent relative factors among 20 clinical data,serological indexes,angiographic findings and stent use for INR were analyzed retrospectively.Results Multivariate Logistic regression analysis showed that independent risk factors for occurrence of ISR were Diabetes mellitus,hyperuricemia,long lesion,calcification lesion,long stent length (＞20 mm) and more stent implantation (OR =1.338、2.468、3.788、11.386、4.182、2.916,P＜0.05).High hs-CRP also is a risk factor(OR=4.183,P=0.068).The higher total bilirubin level and larger stent diameter (＞3 mm)were found to be an independent protective factors of ISR (0R=0.428、0.486,P＜0.05).Conclusion Diabetes mellitus,hyperuricemia,complicated lesions,longer stent length(＞20 mm),and more stent implantation may promote the occurrence of ISR,whereas higher total bilirubin levels and larger stent diameter (＞3 mm) may reduce the occurrence of ISR.